Central Nervous System News and Research

RSS

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

UK scientists find no link between mobile phone masts and early childhood cancers

UK scientists have found no evidence to suggest that children whose mothers lived close to mobile phone base stations during pregnancy face an increased risk of early childhood cancers.

30 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Rexahn announces $10 million registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced it has received commitments from certain institutional investors to purchase an aggregate of $10 million of Rexahn's securities in a registered direct offering.

28 Jun 2010

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests.

28 Jun 2010

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

The nerve cell-damaging plaque that builds up in the brain with Alzheimer's disease also builds up in the retinas of the eyes - and it shows up there earlier, leading to the prospect that noninvasive optical imaging of the eyes could lead to earlier diagnosis, intervention and monitoring of the disease, according to new research.

25 Jun 2010

Investment report on Somaxon Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

25 Jun 2010

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

A white blood cell that normally removes bacteria from the bloodstream helps Escherichia coli (E. coli) accumulate in the blood and enter the brain resulting in the deadly infection known as meningitis. Prasadarao V. Nemani, PhD, a scientist at The Saban Research Institute at Children Hospital Los Angeles plans to find out how this happens with a grant of $1.65 million from the National Institutes of Health - National Institute of Neurological Disorders and Strokes.

25 Jun 2010

Neurosurgeons applaud newly-released draft standards for supervision, duty hours of medical residents

The American Association of Neurological Surgeons, American Board of Neurological Surgery, Congress of Neurological Surgeons, and Society of Neurological Surgeons applaud the newly-released draft standards to revise the national requirements for the supervision and duty hours of medical residents.

25 Jun 2010

UH researchers analyze 'wireless connections' in brain to prevent neurological diseases

Many diseases of brain function, such as epilepsy and schizophrenia, are caused by problems in how neurons communicate with each other. A University of Houston researcher and his team are analyzing these commands and connections in an attempt to prevent those diseases.

25 Jun 2010

UCSD researchers awarded $2.5M CIRM grant to explore stem cells

A pair of University of California San Diego researchers - Martin Marsala, a specialist in spinal cord trauma and disorders, and Yang Xu, an immunologist - have been awarded more than $2.5 million in new grants from the California Institute for Regenerative Medicine.

24 Jun 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

Infusion Nurses Society paper states role of RNs in using IO access devices

The American Association of Critical-Care Nurses recently endorsed "The Role of the Registered Nurse in the Insertion of Intraosseous Access Devices," an official position paper from the Infusion Nurses Society, Norwood, Mass.

23 Jun 2010

No increased risk of childhood cancer if born near mobile phone stations: Study

There have been concerns regarding increased risk for cancer in children born to mothers who lived near mobile phone stations during their pregnancy after a report of a cluster of childhood cancer cases near such stations. A newly published study in the British Medical Journal refutes such beliefs and has found no link to early childhood cancers and living near mobile phone masts.

22 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Valeant, Biovail announce definitive merger agreement

Valeant today announced that both companies' Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc.

21 Jun 2010

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

18 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

This bacterium, Escherichia coli K1, is the most common cause of meningitis in premature infants and the second most common cause of the disease in newborns. "The ineffectiveness of antibiotics in treating newborns with meningitis and the emergence of antibiotic-resistant strains of bacteria require new strategies," explains Nemani V. Prasadarao, PhD, associate professor of infectious disease at Childrens Hospital Los Angeles.

17 Jun 2010

Central Nervous System News and Research

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Renowned experts discuss new approaches to cancer therapy at international conference

UK scientists find no link between mobile phone masts and early childhood cancers

BBD reports analyze effectiveness and safety of statin use

Rexahn announces $10 million registered direct offering

AMP comments on barriers to market for molecular diagnostic tests at FDA CDRH meeting

Scientists discover characteristic amyloid plaques in retinas from Alzheimer's disease patients

Investment report on Somaxon Pharmaceuticals

Scientist at Children Hospital Los Angeles receives NIH grant to research on meningitis

Neurosurgeons applaud newly-released draft standards for supervision, duty hours of medical residents

UH researchers analyze 'wireless connections' in brain to prevent neurological diseases

UCSD researchers awarded $2.5M CIRM grant to explore stem cells

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

Infusion Nurses Society paper states role of RNs in using IO access devices

No increased risk of childhood cancer if born near mobile phone stations: Study

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Valeant, Biovail announce definitive merger agreement

Trial eases concerns over effects of gamma secretase inhibitors for Alzheimer's disease treatment

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Studies suggest role for IL-10 in prevention and treatment of neurological disease in newborns

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News